OpenAlex
PricingAboutJobs
Log inGet started
Work

Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer

HTML

Year: 2005
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Oncology
DOI: 10.1159/000086971
Authors: M. Karthaus, Harald Ballo, Wolgang Abenhardt, Tilmann Steinmetz, Thomas Geer, Jörg Schimke, Dietrich Braumann, Rüdiger Behrens, Dirk Behringer, Manfred Kindler, Helmut Messmann, Hans-Peter Boeck, Roland Greinwald, Ulrich Kleeberg
Institutions: Evangelisches Krankenhaus Bielefeld, Institut für Hämatopathologie Hamburg, Praxis für Hämatologie und Onkologie, University Medical Center Freiburg, University Hospital Regensburg, University of Regensburg, Dr Falk Pharma (Germany)
Language: English

Topic: Cancer therapeutics and mechanisms
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: budesonide, irinotecan, chemotherapy-induced diarrhea, advanced colorectal cancer, diarrhea prevention, loperamide, glucocorticoids, adverse drug reactions
SDG: Good health and well-being

Open Access status: closed

Funders: Dr. Falk Pharma, National Cancer Institute
OpenAlex ID: W2041066142
FWCI: 0.645
Cites: 26
Cited by: 52
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security